VALIRX PLC Logo

VALIRX PLC

VAL | IL

Overview

Corporate Details

ISIN(s):
GB00BLH13C52
LEI:
213800VQKB9SJCQDET40
Country:
United Kingdom
Address:
STONEBRIDGE HOUSE, CM22 7BD HATFIELD HEATH
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

ValiRx PLC is a life science company focused on the early-stage development of therapeutics and diagnostics, primarily in the fields of oncology and women's health. The company's strategy is to accelerate the translation of innovative science into clinical-stage treatments. ValiRx provides scientific, financial, and commercial support to progress its collaborative pipeline of drug candidates, with expertise in epigenomic and genetic analysis. Through its subsidiary, Inaphaea BioLabs, the company offers preclinical and evaluation services, aiming to create an integrated approach to the diagnosis, treatment, and prognosis of diseases to improve patient lives.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for VALIRX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 11:51
Regulatory News Service
ValiRx Awarded Grant from Open University
English 16.2 KB
2025-08-05 10:53
M&A Activity
Update on Evaluation Agreement with Stingray Bio
English 17.9 KB
2025-08-04 08:00
M&A Activity
Licensing Agreement with Dominion Biotech Ltd
English 16.3 KB
2025-07-29 08:00
M&A Activity
Collaboration Agreement with Voxcell BioInnovation
English 17.2 KB
2025-06-20 08:00
M&A Activity
Ambrose Exercise Option on VAL401
English 16.9 KB
2025-06-06 11:54
Major Shareholding Notification
Holding(s) in Company
English 54.3 KB
2025-06-06 08:00
Annual Report
Final Results & Notice of AGM
English 174.1 KB
2025-06-03 08:00
Regulatory News Service
New Evaluation and Material Transfer Agreement
English 15.3 KB
2025-03-27 08:00
Board/Management Information
Directorate Changes and new Advisory Board
English 20.7 KB
2025-02-24 08:00
Regulatory News Service
Conclusion of Evaluation Project
English 15.0 KB
2025-02-03 08:00
Regulatory News Service
Inaphaea Evaluation and Commercial Use Agreement
English 17.0 KB
2025-01-30 08:00
M&A Activity
Extension of Evaluation Agreement
English 15.0 KB
2025-01-29 08:00
M&A Activity
New Evaluation and Option Agreement
English 15.5 KB
2025-01-15 13:47
Major Shareholding Notification
Holding(s) in Company
English 22.1 KB
2025-01-15 12:29
Major Shareholding Notification
Holding(s) in Company
English 54.3 KB

Automate Your Workflow. Get a real-time feed of all VALIRX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for VALIRX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN
Lidds AB Logo
Develops a drug delivery platform for local, sustained-release oncology treatments.
Sweden LIDDS
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies to restore function in neurological & retinal diseases.
Israel LCTX
Lipidor AB Logo
Develops topical skin disease drugs using a lipid-based drug delivery platform.
Sweden LIPI
Lipigon Pharmaceuticals AB Logo
Develops RNA and small-molecule drugs for rare, lipid-related disorders.
Sweden LPGO
Lipum AB Logo
Develops novel antibody therapies for chronic inflammatory diseases like rheumatoid arthritis.
Sweden LIPUM
LYSOGENE Logo France LYS
Lytix Biopharma AS Logo
Develops oncolytic peptides that kill cancer cells and stimulate an anti-tumor immune response.
Norway LYTIX
Matricelf Ltd. Logo
Engineering autologous 3D tissue implants from patient cells to treat spinal cord injuries.
Israel MTLF
Mazaro N.V. Logo
Engineering patented, high-efficiency transmissions for vehicles and industrial drivelines.
Belgium MLMAZ